" class="no-js "lang="en-US"> Anocca - Medtech Alert
Saturday, June 15, 2024
Anocca | Pharmtech Focus


About Anocca


Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity.

Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity.

Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.

Related Story

Anocca Secures €25 Million from the European Investment Bank to Support Development of T-cell Therapies for Cancer

December 21 2022

Anocca, a fully integrated cell therapy biotechnology company, has announced that it has secured €25 […]

Anocca Appoints Jacob Michlewicz as CFO

September 8 2021

Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics, […]